Tracking the CRVS option chain helps you see every strike and expiry on Corvus Pharmaceuticals Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Corvus Pharmaceuticals Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of CRVS options activity at a glance. Use our scanner to monitor the CRVS option chain in real time and filter for the CRVS options trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For CRVS stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the CRVS option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where CRVS stock options are being actively traded and where they are not.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer.
Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Corvus Pharmaceuticals Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen CRVS options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of CRVS stock options — let the full option chain come to you, pre-filtered and ready to trade.
